The MATCH (Medication Aids for Tobacco Cessation and Health) Study
MATCH
Evaluating the Real-world Effectiveness of Varenicline and Bupropion for Long-term Smoking Cessation
1 other identifier
interventional
968
1 country
1
Brief Summary
Clinically proven medications such as nicotine replacement therapy, bupropion and varenicline are available to help smokers quit but there are not widely used. The primary objective of this study is to evaluate the real-world long-term effectiveness of of bupropion and varenicline treatment in a community sample of smokers interested in quitting. The investigators hypothesize that varenicline treatment will result in higher quit rates at end of treatment and at one year after treatment compared to bupropion. Smoking status will be biochemically confirmed at various time points using salivary cotinine measures. Furthermore, since 50% of the variation in quit success is genetically determined, and the effectiveness of different cessation medication may differ considerably in sub-groups of smokers carrying certain genetic variants, the investigators will collect saliva samples from consenting participants to evaluate the moderating effect of genetics on treatment response.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started May 2014
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2014
CompletedFirst Submitted
Initial submission to the registry
May 20, 2014
CompletedFirst Posted
Study publicly available on registry
May 26, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2016
CompletedFebruary 2, 2017
January 1, 2017
2.7 years
May 20, 2014
January 31, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in smoking status over time
Related to effectiveness of smoking cessation intervention, The 7-day point prevalence abstinent rate is defined as not having smoked, even a puff, over the previous seven days.
At 12, 26, and 52 weeks following start of treatment
Secondary Outcomes (2)
Pre-post Decisional Balance Scores
upon first patient enrolled and 1 month following last patient enrolled
Continuous Abstinence
12, 26 and 52 weeks after start of treatment
Other Outcomes (2)
Genetic Polymorphisms
About 5 weeks following participants' enrollment
Personality Traits
At baseline
Study Arms (2)
Bupropion
EXPERIMENTALBupropion hydrochloride SR, Sandoz Canada, Boucherville, Quebec. Dispense for 12 weeks. One tablet (150mg) once daily for first three days, then twice daily for the remainder of 12 weeks.
Varenicline
EXPERIMENTALVarenicline tartrate (Champix®), Pfizer Canada Inc., Kirkland, Quebec. Dispense for 12 weeks. One tablet (0.5mg) once daily for first three days, then one tablet (0.5 mg) twice daily for next four days, then 1 mg (one 1mg tablet or two 0.5mg tablets) twice daily for the remainder of 12 weeks.
Interventions
The e-mails will include tips on several things other than the medications that participants can do to help them quit smoking. The contents of the emails will vary from week to week. The e-mails will provide tips on ways to create an atmosphere that promotes quitting and staying abstinence. They will also include recommendations on how to address issues with withdrawal symptoms and cravings. In addition, they will provide positive motivational messages by stating facts on benefits of quitting smoking.
Eligibility Criteria
You may qualify if:
- At least 19 years of age
- Smoking at least 10 cigarettes per day
- Smoked daily for at least the past year
- Have an intention of quit smoking in the next 30 days.
You may not qualify if:
- History of psychotic disorder or eating disorder
- Brain injury
- Seizure disorder
- Pregnancy, lactation, or at risk of becoming pregnant
- Allergy or sensitivity to bupropion or varenicline
- Taking monoamine oxidase inhibitors (anti-depressants), thioridazine or Wellbutrin or other medication containing bupropion hydrochloride.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Centre for Addiction and Mental Health, Nicotine Dependence Clinic
Toronto, Ontario, M5T 1P7, Canada
Related Publications (2)
Zhang H, Mansoursadeghi-Gilan T, Hussain S, Veldhuizen S, Le Foll B, Selby P, Zawertailo L. Evaluating the effectiveness of bupropion and varenicline for smoking cessation using an internet-based delivery system: A pragmatic randomized controlled trial (MATCH study). Drug Alcohol Depend. 2022 Mar 1;232:109312. doi: 10.1016/j.drugalcdep.2022.109312. Epub 2022 Feb 9.
PMID: 35151504DERIVEDZawertailo L, Mansoursadeghi-Gilan T, Zhang H, Hussain S, Le Foll B, Selby P. Varenicline and Bupropion for Long-Term Smoking Cessation (the MATCH Study): Protocol for a Real-World, Pragmatic, Randomized Controlled Trial. JMIR Res Protoc. 2018 Oct 18;7(10):e10826. doi: 10.2196/10826.
PMID: 30341043DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Laurie Zawertailo, PhD
Centre for Addiction and Mental Health
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Independent Scientist
Study Record Dates
First Submitted
May 20, 2014
First Posted
May 26, 2014
Study Start
May 1, 2014
Primary Completion
December 31, 2016
Study Completion
December 31, 2016
Last Updated
February 2, 2017
Record last verified: 2017-01